spacer
home > ebr > summer 2003 > are patents the beating heart of your boardroom?
PUBLICATIONS
European Biopharmaceutical Review

Are Patents the Beating Heart of your Boardroom?

Most companies do not yet understand that intellectual property (IP) is a lifeline in the brutally competitive world we now face. If you don't believe me here is a quick and easy way to determine the level of IP knowledge in your organisation.

Ask around your colleagues, or even better your boardroom, this simple question: how many years can a court enforce your patents, copyright and trademarks upon other companies?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Ian Harvey, Chief Executive Officer of BTG plc and Chairman of the Government's Intellectual Property Advisory Committee

Ian Harvey is the CEO of BTG, a global technology commercialisation company. He is also Chairman of both the Intellectual Property Institute and the DTI's Intellectual Property Advisory Committee. He joined BTG in 1985 as Chief Executive having spent 10 years with Vickers and Laporte Industries and seven years with the World Bank. Between 1988 and 1993 he served as a member of the Prime Minister's Advisory Council on Science and Technology.

Ian is a Fellow of Nottingham University (1994), and a Member of the Advisory Panel for Science and Technology Policy Research of Sussex University (SPRU) since 1989. He has an MA in Mechanical Sciences from Cambridge University and an MBA from Harvard University.

spacer
Ian Harvey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo keeps growing in the first quarter of 2019

Maintaining its accomplished operations from Ataturk and Istanbul airports as "Dual Hub", the global brand of Turkish Cargo continued its strong growth momentum during the first quarter of the year despite the shrinkage of the global air cargo sector.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was 271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement